Market Access Archives

Blog

‘Most Favored Nation’ Policy Could Have Profound Impact on Global Drug Pricing if Fully Implemented

Editor’s Note: Jiwon Oh provided research support for this article. She is a Certara Market…

CertaraMay 23, 2025

White Paper

Everything you need to know about ILAP 2.0

This white paper share’s key insights on the relaunch of MHRA’s Innovative Licensing and Access…

CertaraMay 19, 2025

Brochure

Establish and communicate your healthcare product’s value

CertaraOctober 9, 2024

Case Study

Joint Clinical Assessment (JCA) And Potential Consequences For The Evaluation Of Gene Therapies

In October 2019, Galderma announced that the U.S. FDA approved AKLIEF® (trifarotene) Cream, 0.005% for the…

CertaraJune 17, 2024

Case Study

Accelerating a drug launch with value communication technology and an integrated workflow

With early approvals for a targeted cancer drug in Brazil and Argentina, this global pharmaceutical…

CertaraOctober 2, 2023

Case Study

Using customer engagement technology to create value communication tools for ABILIFY MAINTENA® (aripiprazole)

Otsuka identified several weaknesses in their existing workflow for developing value communication tools. In particular,…

CertaraOctober 2, 2023

Case Study

Using Real-World Evidence to Derive an External Control Arm for a Rare Disease Drug Trial

Our client was developing a new anti-viral drug for a rare, life-threatening viral infection that…

CertaraApril 17, 2023

Case Study

Using Real World Evidence to Inform Treatment Guidelines

Real-World Evidence (RWE) has become increasingly valuable in informing the development of treatment guidelines for…

CertaraApril 5, 2023

Case Study

Using Real Word Evidence to Enhance Drug Development

Real-world evidence (RWE) has emerged as an increasingly important tool in the drug development process,1…

CertaraApril 5, 2023

Case Study

Agent-Based Model Predicts Impact of Monoclonal Antibody Treatment, Prophylaxis & Vaccines on Viral Transmission during Pandemic

Agent-based models focus on the heterogeneous behavior of individual agents and their interactions with one…

CertaraMarch 2, 2023

Market Access

‘Most Favored Nation’ Policy Could Have Profound Impact on Global Drug Pricing if Fully Implemented

Everything you need to know about ILAP 2.0

Establish and communicate your healthcare product’s value

Joint Clinical Assessment (JCA) And Potential Consequences For The Evaluation Of Gene Therapies

Accelerating a drug launch with value communication technology and an integrated workflow

Using customer engagement technology to create value communication tools for ABILIFY MAINTENA® (aripiprazole)

Using Real-World Evidence to Derive an External Control Arm for a Rare Disease Drug Trial

Using Real World Evidence to Inform Treatment Guidelines

Using Real Word Evidence to Enhance Drug Development

Agent-Based Model Predicts Impact of Monoclonal Antibody Treatment, Prophylaxis & Vaccines on Viral Transmission during Pandemic

Newsletter sign up

Quick links

Solutions

Contact